a public good project by the
Synthesis
Company
of California

© 2026

G. Yancey Gillespie | doi.page

0 works0 citations0 h-index

G. Yancey Gillespie

Merck & Co., Inc., Rahway, NJ, USA (United States)(US)

Publications by Year

Research Areas

Virus-based gene therapy research, CAR-T cell therapy research, Glioma Diagnosis and Treatment, Herpesvirus Infections and Treatments, Immunotherapy and Immune Responses

Most-Cited Works

→ Intertumoral Heterogeneity within Medulloblastoma Subgroups(2017)1,230 cited
→ Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial(2000)974 cited
→ Subgroup-specific structural variation across 1,000 medulloblastoma genomes(2012)915 cited
Human cytomegalovirus infection and expression in human malignant glioma.(2002)
→ Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology.(1993)532 cited
→ Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate(1998)443 cited
→ Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma

(2009)

415 cited

→ Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre-and Post-tumor Resection for Recurrent GBM(2008)401 cited

→ Cross-species genomics matches driver mutations and cell compartments to model ependymoma(2010)362 cited

Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer.(1998)